Diaminopropanol tetraacetic acid

Generic Name: Diaminopropanol tetraacetic acid

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₈N_₂O_₉

CAS Number: 3148-72-9

Unique Ingredient Identifier: 949B9ZMO7M

Background: Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.

Clinical Trials

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

Phase 3

Completed

Conditions: Myocardial Infarction, Acute
Left Ventricular Thrombus

Interventions: Drug: DAPT strategy
Drug: Rivaroxaban 2.5 MG [Xarelto]

First Posted Date: 2021-10-14

Last Posted Date: 2024-07-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 560

Registration Number: NCT05077683

Locations: 🇫🇷
HEGP, Paris, France

Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

Not Applicable

Completed

Conditions: Coronary Artery Disease
Myocardial Infarction, Acute

Interventions: Drug: Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)
Drug: Standard DAPT

First Posted Date: 2021-02-15

Last Posted Date: 2025-05-08

Lead Sponsor: MicroPort CRM

Target Recruit Count: 2248

Registration Number: NCT04753749

Locations: 🇳🇱
Maastad University Hospital, Rotterdam, Netherlands
🇮🇹
Giovanni Paolo II, Ragusa, Italy
🇪🇸
Clinic Hospital Barcelona, Barcelona, Spain

and more 37 locations

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

Phase 4

Active, not recruiting

Conditions: Acute Coronary Syndrome

Interventions: Drug: 1-month DAPT
Drug: No aspirin

First Posted Date: 2020-10-30

Last Posted Date: 2024-06-14

Lead Sponsor: Kyoto University, Graduate School of Medicine

Target Recruit Count: 6002

Registration Number: NCT04609111

Locations: 🇯🇵
Kyoto University Graduate School of Medicine, Kyoto, Japan

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

Phase 4

Recruiting

Conditions: Atrial Fibrillation
Atrial Flutter
Stent Thrombosis
Acute Coronary Syndrome
Embolism
Myocardial Infarction
NSTEMI - Non-ST Segment Elevation MI
STEMI - ST Elevation Myocardial Infarction
Bleeding
Stroke

Interventions: Drug: 30-day DAPT
Drug: Guideline-directed therapy

First Posted Date: 2020-06-18

Last Posted Date: 2023-12-15

Lead Sponsor: St. Antonius Hospital

Target Recruit Count: 2000

Registration Number: NCT04436978

Locations: 🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇧🇪
Imelda Ziekenhuis, Bonheiden, Belgium
🇳🇱
Hagaziekenhuis, Den Haag, Netherlands

and more 17 locations

Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO

Phase 4

Recruiting

Conditions: Left Atrial Appendage Thrombosis
Thrombi
Stroke

Interventions: Drug: DAPT
Drug: Rivaroxaban

First Posted Date: 2019-10-23

Last Posted Date: 2022-11-15

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 826

Registration Number: NCT04135677

Locations: 🇨🇳
Zhongshan Hospital, Fudan Univerisity, Shanghai, Shanghai, China

Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES

Phase 4

Active, not recruiting

Conditions: Coronary Artery Disease
Acute Coronary Syndrome
Chronic Coronary Syndrome
Myocardial Infarction

Interventions: Device: Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
Device: Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
Drug: Personalized DAPT duration
Drug: Standard DAPT duration

First Posted Date: 2019-10-23

Last Posted Date: 2024-02-23

Lead Sponsor: Federico II University

Target Recruit Count: 2106

Registration Number: NCT04135989

Locations: 🇮🇹
Casa di Cura Villa Dei Fiori, Acerra, Naples, Italy
🇮🇹
Ospedale S.Maria delle Grazie, Pozzuoli, Naples, Italy
🇮🇹
A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy

and more 10 locations

XIENCE 28 USA Study

Not Applicable

Completed

Conditions: Thrombocytopenia
Coagulation Disorder
Anemia
Renal Insufficiency
Coronary Artery Disease
Bleeding Disorder
Ischemic Stroke
Hemorrhagic Stroke
Hematological Diseases

Interventions: Device: XIENCE
Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)

First Posted Date: 2019-01-24

Last Posted Date: 2022-05-03

Lead Sponsor: Abbott Medical Devices

Target Recruit Count: 1605

Registration Number: NCT03815175

Locations: 🇺🇸
Clearwater Cardiovascular Consultants, Clearwater, Florida, United States
🇺🇸
Charleston Area Medical Center, Charleston, West Virginia, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

and more 108 locations

Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial

Not Applicable

Recruiting

Conditions: Coronary Artery Disease, Acute Coronary Syndrome

Interventions: Drug: Standard DAPT
Drug: Very-short DAPT less than 1 month after PCI

First Posted Date: 2019-01-09

Last Posted Date: 2023-03-07

Lead Sponsor: Yonsei University

Target Recruit Count: 2850

Registration Number: NCT03797651

Locations: 🇰🇷
Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Phase 4

Active, not recruiting

Conditions: Acute Myocardial Infarction
Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Coronary Artery Disease
Percutaneous Coronary Intervention

Interventions: Drug: 12-month DAPT
Drug: 1-months DAPT

First Posted Date: 2018-03-12

Last Posted Date: 2024-06-14

Lead Sponsor: Kyoto University, Graduate School of Medicine

Target Recruit Count: 3008

Registration Number: NCT03462498

Locations: 🇯🇵
Kyoto University Graduate School of Medicine, Kyoto, Japan

XIENCE 28 Global Study

Not Applicable

Completed

Conditions: Hematological Disease
Renal Insufficiency
Stroke Hemorrhagic
Thrombocytopenia
Anemia
Bleeding Disorder
Stroke, Ischemic
Coagulation Disorder
Coronary Artery Disease

Interventions: Device: XIENCE
Drug: DAPT

First Posted Date: 2017-11-28

Last Posted Date: 2021-03-04

Lead Sponsor: Abbott Medical Devices

Target Recruit Count: 963

Registration Number: NCT03355742

Locations: 🇸🇬
National Heart Centre Singapore, Singapore, Central, Singapore
🇸🇬
Tan Tock Seng Hospital, Singapore, Central, Singapore
🇨🇭
Luzerner Kantonsspital, Luzern, Switzerland

and more 49 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy